Related Experiment Video
Updated: Apr 15, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
11.5K
Multicenter trials, guidelines, and uncertainties - Do we know as much as we think we do?
1Department of Medicine, McGill University Health Center, Montreal, Quebec, Canada; Department of Epidemiology and Biostatistics, McGill University, Montreal, Quebec, Canada.
International Journal of Cardiology
|April 13, 2015
Summary
Large multicenter randomized clinical trials are often seen as definitive truth, but this abstract highlights their limitations. Critical evaluation is needed to avoid overstating precision and making inappropriate guideline recommendations.
Area of Science:
- Clinical Trials Methodology
- Evidence-Based Medicine
- Research Integrity
Background:
- Large-scale multicenter randomized clinical trials (RCTs) are widely accepted as providing definitive evidence.
- However, an uncritical reliance on these trials overlooks inherent limitations and potential biases.
- The backbone of clinical guidelines often rests on these trials, necessitating a thorough understanding of their constraints.
Purpose of the Study:
- To discuss the limitations and difficulties associated with performing large-scale multicenter randomized clinical trials.
- To emphasize the critical need for transparent acknowledgment of residual uncertainties in trial results.
- To explore how overlooking evidential limitations can lead to flawed conclusions and recommendations.
Main Methods:
- Discussion of inherent limitations in large-scale multicenter randomized clinical trials.
- Analysis of potential biases arising from trial "outsourcing" and regional variations.
- Critical evaluation of evidential limitations and their impact on precision estimates.
Main Results:
- Failure to account for regional variations in "outsourced" trials can lead to inaccurate precision estimates.
- Overlooking evidential limitations in large trials can result in the minimization of residual uncertainties.
- The uncritical acceptance of trial "truth" can lead to inappropriate clinical guideline recommendations.
Conclusions:
- A critical and transparent approach to evaluating large-scale randomized clinical trials is essential.
- Acknowledging residual uncertainties is crucial for accurate interpretation of trial findings.
- Improved critical appraisal of trial limitations will lead to more appropriate and reliable clinical guidelines.
Related Concept Videos
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:16Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
575
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
575
01:27Confounding in Epidemiological Studies
1.1K
Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This...
1.1K
01:13Bioequivalence studies: Biowaivers
414
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
414
01:29Bias in Epidemiological Studies
1.7K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.7K